

Optimizing Cardiovascular Risk Reduction in High-Risk Patients Through Lipid Management

Abbreviations, Acronyms, Initialisms

ACC	American College of Cardiology
ACS	acute coronary syndrome
AHA	American Heart Association
apo B	apolipoprotein B
ARR	absolute risk reduction
ASCVD	atherosclerotic cardiovascular disease
BMI	body mass index
BP	blood pressure
CAD	coronary artery disease
CI	confidence interval
CIMT	carotid intima-media thickness
CKD	chronic kidney disease
CV	cardiovascular
DM	diabetes mellitus
eGFR	estimated glomerular filtration rate
FH	familial hypercholesterolemia
HbA1c	glycated hemoglobin
HCTZ	hydrochlorothiazide
HDL-C	high-density lipoprotein cholesterol
HeFH	heterozygous familial hypercholesterolemia
HoFH	homozygous familial hypercholesterolemia
HTN	hypertension
IAS	International Atherosclerosis Society
IFG	impaired fasting glucose
LDL-C	low-density lipoprotein cholesterol
LLT	lipid-lowering therapy
MACE	major adverse cardiovascular events
MetS	metabolic syndrome
MI	myocardial infarction
NCEP-ATP	National Cholesterol Education Panel—Adult Treatment Panel
NHLBI	National Heart, Lung, and Blood Institute
NLA	National Lipid Association
NNT	number needed to treat
non-HDL-C	non-high-density lipoprotein cholesterol
PCSK9	proprotein convertase subtilisin/kexin type 9
q2w	every 2 weeks
RAASi	renin-angiotensin-aldosterone system inhibitor
RRR	relative risk reduction
SC	subcutaneous
T1DM	type 1 diabetes mellitus
T2DM	type 2 diabetes mellitus
TG	triglycerides
wks	weeks
y	year(s)

